出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/07/23 08:37:11」(JST)
| Uterine fibroids | |
|---|---|
| Classification and external resources | |
Uterine Fibroids
|
|
| ICD-10 | D25 |
| ICD-9 | 218.9 |
| OMIM | 150699 |
| DiseasesDB | 4806 |
| MedlinePlus | 000914 |
| eMedicine | radio/777 |
| MeSH | D007889 |
A uterine fibroid is a leiomyoma (benign (non-cancerous) tumor from smooth muscle tissue) that originates from the smooth muscle layer (myometrium) of the uterus. Fibroids are often multiple and garner the designation of diffuse uterine leiomyomatosis if they are randomly located and many in numbers. There is a malignant form of a fibroid and fibroids can rarely (0.1-0.5%), undergo malignant degeneration into leiomyosarcoma. Additionally there are rare forms of fibroids where the lesions are capable of metastasising without malignant transformation and this process is called benign metastasising leiomyoma.
Other common names are uterine leiomyoma,[1] myoma, fibromyoma, fibroleiomyoma.
Fibroids are the most common benign tumors in females and typically found during the middle and later reproductive years. While most fibroids are asymptomatic, they can grow and cause heavy and painful menstruation, painful sexual intercourse, and urinary frequency and urgency. Some fibroids may interfere with pregnancy although this appears to be very rare.[2]
In the United States, symptoms caused by uterine fibroids are a very frequent indication for hysterectomy.[3]
Fibroids, particularly when small, may be entirely asymptomatic. Symptoms depend on the location of the lesion and its size. Important symptoms include abnormal gynecologic hemorrhage, heavy or painful periods, abdominal discomfort or bloating, painful defecation, back ache, urinary frequency or retention, and in some cases, infertility.[4] There may also be pain during intercourse, depending on the location of the fibroid. During pregnancy they may also be the cause of miscarriage, bleeding, premature labor, or interference with the position of the foetus.
While fibroids are common, they are not a typical cause for infertility accounting for about 3% of reasons why a woman may not have a child.[5] Typically in such cases a fibroid is located in a submucosal position and it is thought that this location may interfere with the function of the lining and the ability of the embryo to implant.[5] Also larger fibroids may distort or block the fallopian tubes.
Leiomyomata grossly appear as round, well circumscribed (but not encapsulated), solid nodules that are white or tan, and show whorled appearance on histological section. The size varies, from microscopic to lesions of considerable size. Typically lesions the size of a grapefruit or bigger are felt by the patient herself through the abdominal wall.
Microscopically, tumor cells resemble normal cells (elongated, spindle-shaped, with a cigar-shaped nucleus) and form bundles with different directions (whorled). These cells are uniform in size and shape, with scarce mitoses. There are three benign variants: bizarre (atypical); cellular; and mitotically active.
The appearance of prominent nucleoli with perinucleolar halos should alert the pathologist to investigate the possibility of the extremely rare hereditary leiomyomatosis and renal cell cancer syndrome.[6]
Growth and location are the main factors that determine if a fibroid leads to symptoms and problems.[3] A small lesion can be symptomatic if located within the uterine cavity while a large lesion on the outside of the uterus may go unnoticed. Different locations are classified as follows:
Fibroids may be single or multiple. Most fibroids start in an intramural location, that is the layer of the muscle of the uterus. With further growth, some lesions may develop towards the outside of the uterus or towards the internal cavity. Secondary changes that may develop within fibroids are hemorrhage, necrosis, calcification, and cystic changes.
Fibroids of uterine origin located in other parts of the body, sometimes also called parasitic myomas have been historically extremely rare, but are now diagnosed with increasing frequency. They may be related or identical to metastasizing leiomyoma.
They are in most cases still hormone dependent but may cause life threatening complications when they appear in distant organs. Some sources suggest that a substantial share of the cases may be late complications of surgeries such as myomectomy or hysterectomy. Particularly laparoscopic myomectomy using a morcellator has been associated with a substantially increased risk of this complication.[7][8][9][10][11]
Fibroids are monoclonal tumors and approximately 40 to 50% show karyotypically detectable chromosomal abnormalities. When multiple fibroids are present they frequently have unrelated genetic defects. Specific mutations of the MED12 protein have been noted in 70 percent of fibroids.[12]
Exact aetiology is not clearly understood, but the current working hypothesis is that genetic predispositions, prenatal hormone exposure and the effects of hormones, growth factors and xenoestrogens cause fibroid growth. Known risk factors are African descent, nulliparity, obesity, polycystic ovary syndrome, diabetes and hypertension.[13]
Fibroid growth is strongly dependent on estrogen and progesterone. Although both estrogen and progesterone are usually regarded as growth-promoting they will also cause growth restriction in some circumstances. Paradoxically, fibroids rarely grow during pregnancy despite very high steroid hormone levels and pregnancy appears to exert a certain protective effect.[2] This protective effect might be partially mediated by an interaction between estrogen and the oxytocin receptor.[14]
It is believed that estrogen and progesterone have a mitogenic effect on leiomyoma cells and also act by influencing (directly and indirectly) a large number of growth factors, cytokines and apoptotic factors as well as other hormones. Furthermore, the actions of estrogen and progesterone are modulated by the cross-talk between estrogen, progesterone and prolactin signalling which controls the expression of the respective nuclear receptors. It is believed that estrogen promotes growth by up-regulating IGF-1, EGFR, TGF-beta1, TGF-beta3 and PDGF, and promotes aberrant survival of leiomyoma cells by down-regulating p53, increasing expression of the anti-apoptotic factor PCP4 and antagonizing PPAR-gamma signalling. Progesterone is thought to promote the growth of leiomyoma through up-regulating EGF, TGF-beta1 and TGF-beta3, and promotes survival through up-regulating Bcl-2 expression and down-regulating TNF-alpha. Progesterone is believed to counteract growth by downregulating IGF-1.[15][16][17] Expression of transforming growth interacting factor (TGIF) is increased in leiomyoma compared with myometrium.[18] TGIF is a potential repressor of TGF-β pathways in myometrial cells.[18]
Whereas in premenopausal fibroids the ER-beta, ER-alpha and progesterone receptors are found overexpressed, in the rare postmenopausal fibroids only ER-beta was found significantly overexpressed.[19] Most studies found that polymorphisms in ER and PR gene encodings are not correlated with incidence of fibroids in Caucasian populations[20][21] however a special ER-alpha genotype was found correlated with incidence and size of fibroids. The higher prevalence of this genotype in black women may also explain the high incidence of fibroids in this group.[22]
Uterine leiomyoma was more sensitive than normal myometrium to PPAR-gamma receptor activation resulting in reduced survival and apoptosis of leiomyoma cells. The mechanism is thought to involve negative cross-talk between ER and PPAR signaling pathways. Several PPAR-gamma ligands were considered as potential treatment.[23] PPAR-gamma agonists may also counteract leiomyoma growth by several other mechanisms of action such as TGF-beta3 expression inhibition.[24]
Hypertension is significantly correlated with fibroids. Although a causal relationships is not at all clear the hypothesis has been formulated that atherosclerotic injury to uterine blood vessels and the resulting inflammatory state may play a role. Furthermore endocrine factors related to blood pressure such as angiotensin II are suspected to cause fibroid proliferation via angiotensin II type 1 receptor.[25][26]
Aromatase and 17beta-hydroxysteroid dehydrogenase are aberrantly expressed in fibroids, indicating that fibroids can convert circulating androstenedione into estradiol.[27] Similar mechanism of action has been elucidated in endometriosis and other endometrial diseases.[28] Aromatase inhibotors are currently considered for treatment, at certain doses they would completely inhibit estrogen production in the fibroid while not largely affecting ovarian production of estrogen (and thus systemic levels of it). Aromatase overexpression is particularly pronounced in Afro-American women[29]
Genetic and hereditary causes are being considered and several epidemiologic findings indicate considerable genetic influence especially for early onset cases. First degree relatives have a 2.5-fold risk, and nearly 6-fold risk when considering early onset cases. Monozygotic twins have double concordance rate for hysterectomy compared to dizygotic twins.[30]
Like keloids, fibroids have disregulated production of extracellular matrix. Recent studies suggest that this production may represent an abnormal response to ischemic and mechanical tissue stress.[31] Several factors indicate significant involvement of extracellular signaling pathways such as ERK1 and ERK2, which in fibroids are prominently influenced by hormones.[32] Paradoxically and unlike most other conditions involving significant fibrosis the Cyr61 gene has been found downregulated in fibroids.[33]
Cyr61 is also known for its role as tumor suppressing factor and in angiogenesis. Hence fibroids are one of the very few tumors with reduced vascular density.[33]
While a bimanual examination typically can identify the presence of larger fibroids, gynecologic ultrasonography (ultrasound) has evolved as the standard tool to evaluate the uterus for fibroids. Sonography will depict the fibroids as focal masses with a heterogeneous texture, which usually cause shadowing of the ultrasound beam. The location can be determined and dimensions of the lesion measured. Also magnetic resonance imaging (MRI) can be used to define the depiction of the size and location of the fibroids within the uterus.
Imaging modalities cannot clearly distinguish between the benign uterine leiomyoma and the malignant uterine leiomyosarcoma, however, the latter is quite rare. Fast growth or unexpected growth, such as enlargement of a lesion after menopause, raise the level of suspicion that the lesion might be a sarcoma. Also, with advanced malignant lesions there may be evidence of local invasion. A more recent study has suggested that diagnostic capabilities using MRI have improved the ability to detect sarcomatous lesions.[34] Biopsy is rarely performed and if performed, is rarely diagnostic. Should there be an uncertain diagnosis after ultrasounds and MRI imaging, surgery is generally indicated.
Other imaging techniques that may be helpful specifically in the evaluation of lesions that affect the uterine cavity are hysterosalpingography or sonohysterography.
A very large (9 cm) fibroid of the uterus which is causing pelvic congestion syndrome as seen on CT
A very large (9 cm) fibroid of the uterus which is causing pelvic congestion syndrome as seen on ultrasound
A relatively large submucosal leiomyoma; it fills out the major part of the endometrial cavity
A small uterine fibroid seen within the wall of the myometrium on a cross sectional ultrasound view
Two calcified fibroids (in the uterus)
Fibroids that lead to heavy vaginal bleeding lead to anemia and iron deficiency. Due to pressure effects gastrointestinal problems are possible such as constipation and bloatedness. Compression of the ureter may lead to hydronephrosis. Fibroids may also present alongside endometriosis, which itself may cause infertility. Adenomyosis may be mistaken for or coexist with fibroids.
In very rare cases, malignant (cancerous) growths, leiomyosarcoma, of the myometrium can develop.[35]
In extremely rare cases uterine fibroids may present as part or early symptom of the hereditary leiomyomatosis and renal cell cancer syndrome.
Most fibroids do not require treatment unless they are causing symptoms. After menopause fibroids shrink and it is unusual for fibroids to cause problems.
Symptomatic uterine fibroids can be treated by:
A number of medications are in use to control symptoms caused by fibroids. NSAIDs can be used to reduce painful menses. Oral contraceptive pills are prescribed to reduce uterine bleeding and cramps.[5] Anemia may have to be treated with iron supplementation.
Levonorgestrel intrauterine devices are highly effective in limiting menstrual blood flow and improving other symptoms. Side effects are typically very moderate because the levonorgestrel (a progestin) is released in low concentration locally. There is now substantial evidence that Levongestrel-IUDs provide good symptomatic relief for women with fibroids.[36] While most Levongestrel-IUD studies concentrated on treatment of women without fibroids a few reported very good results specifically for women with fibroids including a substantial regression of fibroids.[37][38][39]
Danazol is an effective treatment to shrink fibroids and control symptoms. Its use is limited by unpleasant side effects. Mechanism of action is thought to be antiestrogenic effects. Recent experience indicates that safety and side effect profile can be improved by more cautious dosing.[38]
Dostinex in a moderate and well tolerated dosis has been shown in 2 studies to shrink fibroids effectively. Mechanism of action is unclear.[38][40]
Gonadotropin-releasing hormone analogs cause temporary regression of fibroids by decreasing estrogen levels. Because of the limitations and side effects of this medication it is rarely recommended other than for preoperative use to shrink the size of the fibroids and uterus before surgery. It is typically used for a maximum of 6 months or less because after longer use they could cause osteoporosis and other typically postmenopausal complications. The main side effects are transient postmenopausal symptoms. In many cases the fibroids will regrow after cessation of treatment, however significant benefits may persist for much longer in some cases. Several variations are possible, such as GnRH agonists with add-back regimens intended to decrease the adverse effects of estrogen deficiency. Several add-back regimes are possible, tibolone, raloxifene, progestogens alone, estrogen alone, and combined estrogens and progestogens.[38]
Ulipristal acetate is a synthetic selective progesterone receptor modulator which has been tested in small radomized trials with good results for the treatment of fibroids.[41] Similar to other selective progesterone receptor modulators and antagonists benign histologic endometrial changes were reported and long term safety outside of clinical studies has not been established yet.[41][42][43]
Progesterone antagonists such as Mifepristone have been tested, there is evidence that it relieves some symptoms and improves quality of life but because of adverse histological changes that have been observed in several trials it can not be currently recommended outside of research setting.[44][45][46]Selective progesterone receptor modulators, such as Progenta, have been under investigation.
The selective progesterone receptor modulator Asoprisnil is currently tested with very promising results as a possible use as a treatment for fibroids - the hope is that it will provide the advantages of progesterone antangonitst without their adverse effects.[38]
The long term safety of progesterone antagonists as well as selective progesterone receptor modulators has yet to be established.[47][48]
Aromatase inhibitors have been used experimentally to reduce fibroids. The effect is believed to be due partially by lowering systemic estrogen levels and partially by inhibiting locally overexpressed aromatase in fibroids.[38] Experience from experimental aromatase inhibitor treatment of endometriosis indicates that aromatase inhibitors might be particularly useful in combination with a progestogenic ovulation inhibitor.
Uterine artery embolization (UAE): Using interventional radiology techniques, the interventional radiologist occludes both uterine arteries, thus reducing blood supply to the fibroid.[49] This intervention is not usually recommended when fertility should be preserved although subsequent pregnancies are usually possible. A small catheter (1 mm in diameter) is inserted into the femoral artery at the level of the groin under local anesthesia. Under imaging guidance, the interventional radiologist will enter selectively into both uterine arteries and inject small (500 µm) particles that will block the blood supply to the fibroids. A patient will usually recover from the procedure within a few days. The UAE procedure should result in limited blood supply to the fibroids which should prevent them from further growth, heavy bleeding and possibly shrink them.
A retrospective cohort study showed that UAE has much fewer serious adverse effects than hysterectomy (odds ratio 0.25) and similar rates of satisfaction. In this study, 86% of women treated with UAE would recommend the treatment to a friend compared to 70% of those treated by hysterectomy.[50]
Uterine artery ligation, sometimes also laparoscopic occlusion of uterine arteries are minimally invasive methods to limit blood supply of the uterus by a small surgery that can be performed transvaginally or laparoscopically. The principal mechanism of action may be similar like in UAE but is easier to perform and fewer side effects are expected.[51][52][53] UAE currently appears much more effective than this method in direct comparison.[54]
Radiofrequency ablation is one of the newest minimally invasive treatments for fibroids.[55] In this technique the fibroid is shrunk by inserting a needle-like device into the fibroid through the abdomen and heating it with radio-frequency (RF) electrical energy to cause necrosis of cells. The treatment is a potential option for women who have fibroids, have completed child-bearing and want to avoid a hysterectomy.
Myomectomy is a surgery to remove one or more fibroids. It is usually recommended when more conservative treatment options fail for women who want fertility preserving surgery or who want to retain the uterus.[56]
There are three types of myomectomy:
Hysterectomy was the classical method of treating fibroids. Although it is now recommended only as last option, fibroids are still the leading cause of hysterectomies in the US.
Endometrial ablation can be used if the fibroids are only within the uterus and not intramural and relatively small. High failure and recurrence rates are expected in the presence of larger or intramural fibroids.
Magnetic Resonance guided Focused Ultrasound, is a non-invasive intervention (requiring no incision) that uses high intensity focused ultrasound waves to destroy tissue in combination with magnetic resonance imaging (MRI), which guides and monitors the treatment. During the procedure, delivery of focused ultrasound energy is guided and controlled using MR thermal imaging.[58] Patients who have symptomatic fibroids, who desire a non-invasive treatment option and who do not have contraindictions for MRI are candidates for MRgFUS. About 60% of patients qualify. It is an outpatient procedure and takes one to three hours depending on the size of the fibroids. It is safe and about 75% effective.[59] Symptomatic improvement is sustained for two plus years.[60] Need for additional treatment varies from 16-20% and is largely dependent on the amount of fibroid that can be safely ablated; the higher the ablated volume, the lower the re-treatment rate.[61] In comparison to available treatment options, the cost effectiveness of MRgFUS in the U.S. and U.K. has been found to be reasonable and comparable to alternative treatments (hysterectomy, pharmacotherapy, uterine artery embolization).[62][63] There are currently no randomized trial between MRgFUS and UAE. A multi-center trial is underway to investigate the efficacy of MRgFUS vs. UAE.
Globally approximately 235 million people are affected with uterine fibroids as of 2010 (6.6% of females).[64] About 20–40% of women will be diagnosed with leiomyoma at some point in their life but only a fraction of those will cause problems or require treatment.[3]
Leiomyomata are more common in obese women.[65] Fibroids are dependent on estrogen and progesterone to grow and therefore relevant only during the reproductive years, they are expected to shrink after menopause.
Uterine leiomyomas are the most common pelvic tumor in women.[66][67][68] A hysterectomy study found myomas in 77 percent of uterine specimens.[69]
The epidemiology of leiomyomas parallels the ontogeny and life cycle changes of the reproductive hormones estrogen and progesterone. Although the growth of fibroids is responsive to gonadal steroids, these hormones are not necessarily responsible for the genesis of the tumors.
Leiomyomas have not been described in prepubertal girls, but they are occasionally noted in adolescents. Myomas are clinically apparent in approximately 12 to 25 percent of reproductive age women and noted on pathological examination in approximately 80 percent of surgically excised uteri.[69] In hysterectomy specimens sectioned at 2-mm intervals, premenopausal women had an average 7.6 fibroids.[69] Most, but not all, women have shrinkage of leiomyomas at menopause.
An association with fatty acid synthase has been reported.[70]
A syndrome (Reed’s syndrome) of cutaneous and uterine leiomyomata and renal cell cancer has been reported.[71][72][73] This is associated with a mutation in the fumarate hydratase which is located on the long arm of chromosome 1 (1q42.3-43). Inheritance is autosomal dominant.
This syndrome is described in greater detail on the page Hereditary leiomyomatosis and renal cell cancer.
Eighty percent of African American women will develop benign uterine fibroid tumors by their late 40s, according to the National Institute of Environmental Health Sciences.[74] African American women are two to three times more likely to get fibroids than Caucasian women.[65][75][76] Also, in African-American women, fibroids also seem to occur at a younger age, grow more quickly, and are more likely to cause symptoms.[77] This leads to higher rates of surgery for African Americans, both myomectomy and hysterectomy.[78] Furthermore, increased risk of fibroids in African- Americans causes them to fare worse in in-vitro fertility treatments and raises their risk of premature births and delivery by Cesarean section.[78]
Research has not proven why fibroids are more common in African American women but there are some speculations. Some studies suggest that black women who are obese and who have high blood pressure are more likely to have fibroids.[78] Additionally, national surveys show that black women consume fewer servings of dairy than white women and have lower intake of calcium, magnesium and phosphorus.[79] Boston University School of Medicine researchers found that increased dairy intake in African American women decreases their risk of fibroids.[79] Additionally, research evidence has demonstrated that women with a family history of fibroids are twice more likely to develop fibroids than women with no family history — thus perpetuating the cycle of fibroid prevalence in African Americans.[78] However, although there is much speculation much more research must be done to determine why fibroid prevalence is higher in African American women.
About 1 out of 1000 lesions[5] are or become malignant, typically as a leiomyosarcoma on histology. A sign that a lesion may be malignant is growth after menopause.[5] There is no consensus among pathologists regarding the transformation of leiomyoma into a sarcoma. Most pathologists believe that a Leiomyosarcoma is a de novo disease[citation needed].
There are a number of rare conditions in which fibroids metastasize. They still grow in a benign fashion, but can be dangerous depending on their location.[80]
The Center for Uterine Fibroids which is associated with Brigham and Women’s Hospital in Boston MA ([1]) is currently recruiting volunteers for an investigation of all aspects of the aetiology, pathology of fibroids and development of treatment options. This institution also has a lot of clinical trials focused on African American women. The focus of one study is the search for a specific gene associated with the development of fibroids. Since one risk factor for uterine fibroids is having a family history of fibroids, the results of this study will provide some answers on the heredity of the illness. Some women may interact with the healthcare system by getting an ultrasound to diagnose symptoms if they’ve had a mother, sister or grandmother who has previously suffered with these benign tumors.
The 2005 S.1289 bill was read twice and referred to the committee on Health, Labor and Pensions but never passed for a Senate or House vote. The proposed Uterine Fibroid Research and Education Act of 2005 mentioned that $5 billion is spent annually on hysterectomy surgeries each year, which affect 22% of African Americans and 7% of Caucasian women. The bill also called for more funding for research and educational purposes. It also states that of the $28 billion issued to NIH,[81] $5 million was allocated for uterine fibroids in 2004.
Uterine fibroids are rare in other mammals, although they have been observed in certain dogs and Baltic gray seals.[82]
|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|url= (help)|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit|displayauthors= suggested (help) edit| Wikimedia Commons has media related to: Uterine fibroids |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
| リンク元 | 「子宮筋腫」 |
| 関連記事 | 「uteri」「myoma」 |
(G9M.128)
| 自覚症状 | 例数（全92例中の%） |
| 腹痛・腰痛・腹部緊満 | 53（57.6） |
| 巨大腫瘤・腫瘤増大 | 39（42.4） |
| 性器出血 | 27（29.3） |
| 筋腫による流産既往 | 3（3.3） |
| 多発筋腫で胎嚢変形 | 3（3.3） |
| 筋腫変性による疼痛反復 | 2（2.2） |
| 水腎症 | 1（1.1） |
| 計 | 128 |
| 子宮筋腫 | 30歳代の女性で過多月経をきたし、内診で硬く腫大した子宮を触れ、超音波で子宮体部に充実性の腫瘤を認める。MRI T2では境界明瞭な低信号を認め、JZは保たれる。 |
| 子宮腺筋症 | 過多月経をきたし、内診ではびまん性に腫大した弾性の子宮を触知。エコーでは子宮筋層の肥厚。MRI T2では境界不明瞭な低信号域(筋層)の中に半流動性の出血を反映する点状の高信号を認め、JZは不明瞭化する。 |
| 子宮体癌 | 中年～高齢女性。子宮内膜(高信号)の増殖、肥厚が見られる。境界明瞭な腫瘤ではない。MRI T2ではJZが断裂している。 |
| 子宮頚癌 | 子宮体部は腫大しない。 |
| 子宮筋腫 | 子宮腺筋症 | |
| Ｔ2強調画像 | 低信号 | |
| 境界 | 明瞭 | 不明瞭 |
| 変性 | さまざまな高信号 | － |
| 異所性内膜 | － | 点状高信号 |
| flow void sign | ＋ | － |